Abstract:Background
Eribulin is a new drug against metastatic breast cancer, one of the most common cancers in women
Purpose
To study the effectiveness and safety of treatment with eribulin in metastatic breast cancer in patients who have been treated with at least two processing lines including anthracyclines and taxanes
Materials and methods
Retrospective descriptive study of patients who received eribulin from marketing until September 2013.
Variables examined: sex, age, hormone receptor and lines of treatment p… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.